Pulmonary Arterial Hypertension

About

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Articles

Assessing Pregnancy Risk in Patients with Congenital Heart Disease

Published:

25 May 2023

Citation:

US Cardiology Review 2023;17:e06.

Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction

Citation:

US Cardiology Review 2018;12(1):8–12.

Impact of Atrial Septal Defect on Hemodynamics

Citation:

US Cardiology Review 2017;11(2):72–4.

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension

Citation:

US Cardiology Review 2016;10(2):78–84